Abstract
Due to developments in diagnosing and treating restless legs syndrome (RLS) over the past decade, there has been a marked increase in the awareness of RLS among both physicians and patients. In fact, it is estimated that 2 % of patients in primary care practices have RLS that is serious and disruptive enough to treat, with the number being diagnosed and treated expected to increase as awareness grows. This chapter aims to provide physicians with guidance to manage this large group of patients properly.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237–46.
Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG. Medical Advisory Board of the Willis-Ekbom Disease Foundation Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88:977–86.
Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B. Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med. 2006;19:487–93.
Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep. 1998;21:371–7.
O’Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23:200–3.
Wang J, O’Reilly B, Venkataraman R, Mysliwiec V, Mysliwiec A. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med. 2009;10:973–5.
Cho YW, Allen RP, Earley CJ. Lower molecular weight intravenous iron dextran for restless legs syndrome. Sleep Med. 2013;14:274–7.
Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12:906–13.
Burbank F, Buchfuhrer MJ, Kopjar B. Sleep improvement for restless legs syndrome patients. Part I: pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RLS symptoms. J Parkinsonism Restless Legs Syndrome. 2013;3:1–10.
Burbank F, Buchfuhrer MJ, Kopjar B. Sleep improvement for restless legs syndrome patients. Part II: pooled analysis of two prospective, double-blind, sham-controlled, multi-center, randomized clinical studies of the effects of vibrating pads on RLS symptoms. J Parkinsonism Restless Legs Syndrome. 2013;3:11–22.
Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol. 1982;39:739.
Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–13.
Maestri M, Fulda S, Ferini-Strambi L, Zucconi M, Marelli S, Staedler C, et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med. 2014;15:570–5.
Garcia-Borreguero D, Allen RP, Silber MH, Winkleman JW, Högl B, Bainbridge B, et al. White paper summary of recommendations for the prevention and treatment of RLS/WED augmentation. A combined task force of the IRLSSG, EURLSSG, and the RLS-Foundation. International Restless Legs Syndrome Study Group website. http://irlssg.org/wp-content/uploads/2015/05/Summary-of-recommendations-RLS-Augmentation-13Aug2015.pdf. Accessed 21 Jan 2016.
Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59:1573–9.
Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, Chen D. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol. 2011;34:8–16.
Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621–31.
Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, Miceli J, Knapp L, Allen RP. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37:635–43.
Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48:1378–88.
Walters AS. Review of receptor agonist and antagonist studies relevant to the opiate system in restless legs syndrome. Sleep Med. 2002;3:301–4.
Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20:345–8.
Trenkwalder C, Beneš H, Grote L, García-Borreguero D, Högl B, Hopp M, Bosse B, RELOXYN Study Group, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–50.
Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry. 1999;60:241–4.
Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006;7:592–3.
Mitler MM, Browman CP, Menh SJ, Gujavarty K, Timms RM, et al. Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam. Sleep. 1986;9:385–92.
Allen RP, Barker PB, Horská A, Earley CJ. Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology. 2013;80:2028–34.
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Monplaisi J, Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.
Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12:431–9.
Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440–4.
Oertel W, Trenkwalder C, Beneš H, Ferini-Strambi L, Högl B, Poewe W, et al. SP710 study group. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10:710–20.
Picchietti DL, Hensley JG, Bainbridge JL, Lee KA, Manconi M, McGregor JA, International Restless Legs Syndrome Study Group (IRLSSG). Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. Sleep Med Rev. 2015;22:64–77.
Molnar MZ, Novak M, Mucsi I. Management of restless legs syndrome in patients on dialysis. Drugs. 2006;66:607–24.
Picchietti DL, Bruni O, de Weerd A, Durmer JS, Kotagal S, Owens JA, Simakajornboon N, International Restless Legs Syndrome Study Group (IRLSSG). Pediatric restless legs syndrome diagnostic criteria: an update by the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:1253–9.
Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment. Sleep Med. 2010;11:643–51.
Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–5.
Kurlan R, Richard IH, Deeley C. Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation. J Gen Intern Med. 2006;21:C1–4.
Kurlan R, Rabin M. Augmentation in restless legs syndrome: poor response to sudden withdrawal of dopaminergic therapy. J Parkinsonism Restless Legs Syndrome. 2013;3:49–52.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Buchfuhrer, M.J. (2016). Management of Restless Legs Syndrome. In: Clinician's Manual on Restless Legs Syndrome. Adis, Cham. https://doi.org/10.1007/978-3-319-31373-3_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-31373-3_5
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-31372-6
Online ISBN: 978-3-319-31373-3
eBook Packages: MedicineMedicine (R0)